Sight Sciences faces Medicare coverage threat for OMNI system; 63% of Surgical Glaucoma revenue at risk

Sight Sciences, Inc.

WPS LCD classifies OMNI procedure as investigational, effective Dec 24, 2023; WPS states ~8% of 2022 Surgical Glaucoma revenue.
Four other MACs proposed similar LCDs; combined five MACs ~63% of 2022 Surgical Glaucoma revenue.
Company evaluating FY 2023 guidance due to uncertain coverage; update on Nov 7 earnings call.
Company disputes LCD, submitted 36-month GEMINI study for publication; will pursue all remediation.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.